Neuroprotective peptides
AssigneeArgenica Therapeutics Pty Ltd
InventorBruno Meloni
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of an isolated peptide of 10 to 32 amino acid residues in length for the treatment of neural injury, wherein the isolated peptide comprises at least 10 to 22 arginine residues. The peptide may be a poly-arg sequence or an arginine-rich peptide.
Claims28
A method for treating a patient for a neural injury from ischemia, perinatal hypoxia-ischemia, traumatic brain injury, or stroke, the method comprising administering to said patient a pharmaceutical composition comprising an effective amount of a poly-arginine peptide having 12 to 18 arginine residues, wherein the pharmaceutical composition does not contain an active pharmaceutical ingredient that is not a poly-arginine peptide.
A method for promoting the survival of neurons and/or inhibiting neuron death in a patient comprising administering to said patient a pharmaceutical composition comprising an effective amount of a polyarginine peptide having 12 to 18 arginine residues, wherein the pharmaceutical composition does not contain an active pharmaceutical ingredient that is not a poly-arginine peptide, and wherein the patient is an ischemia patient, a perinatal hypoxia-ischemia patient, an Alzheimer's disease patient, a Huntington's Disease patient, a Multiple Sclerosis patient, a Parkinson's disease patient, an amyotrophic lateral sclerosis patient, a stroke patient, a peripheral neuropathy patient, a traumatic brain injury patient, a spinal cord injury patient, or an epilepsy patient.
A method for inhibiting neurological damage from an excitotoxic injury, the method comprising administering to a patient a pharmaceutical composition consisting essentially of:
- (i) one or more peptides with an amino acid sequence consisting of 12 to 18 arginine residues;
- and (ii) one or more pharmaceutically acceptable carriers, adjuvants, or vehicles,
- wherein the patient is an ischemia patient, a perinatal hypoxia-ischemia patient, an Alzheimer's disease patient, a Huntington's Disease patient, a Multiple Sclerosis patient, a Parkinson's disease patient, an amyotrophic lateral sclerosis patient, a stroke patient, a peripheral neuropathy patient, a traumatic brain injury patient, a spinal cord injury patient, or an epilepsy patient.
A method for inhibiting neurological damage from an excitotoxic injury, the method comprising administering to a patient a pharmaceutical composition containing only poly-arginine peptides and one or more pharmaceutically acceptable carriers, adjuvants, or vehicles, wherein the composition includes at least one poly-arginine peptide having a length of 12 to 18 amino acids,
- wherein the patient is an ischemia patient, a perinatal hypoxia-ischemia patient, an Alzheimer's disease patient, a Huntington's Disease patient, a Multiple Sclerosis patient, a Parkinson's disease patient, an amyotrophic lateral sclerosis patient, a stroke patient, a peripheral neuropathy patient, a traumatic brain injury patient, a spinal cord injury patient, or an epilepsy patient.
Dependencies are inferred from the claim text.